Patient-centered research: how do women tolerate nipple fluid aspiration as a potential screening tool for breast cancer?

[1]  P. V. van Diest,et al.  Nipple Aspirate Fluid at a Glance , 2021, Cancers.

[2]  P. V. van Diest,et al.  The changing microRNA landscape by color and cloudiness: a cautionary tale for nipple aspirate fluid biomarker analysis , 2021, Cellular Oncology.

[3]  Z. Takáts,et al.  Breast health screening: a UK-wide questionnaire , 2021, BMJ nutrition, prevention & health.

[4]  A. Jemal,et al.  Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries , 2021, CA: a cancer journal for clinicians.

[5]  H. D. de Koning,et al.  Experiences, expectations and preferences regarding MRI and mammography as breast cancer screening tools in women at familial risk , 2021, Breast.

[6]  P. V. van Diest,et al.  Lessons Learned from Setting Up a Prospective, Longitudinal, Multicenter Study with Women at High Risk for Breast Cancer , 2020, Cancer Epidemiology, Biomarkers & Prevention.

[7]  S. Duffy,et al.  Breast Cancer Screening and Diagnosis: A Synopsis of the European Breast Guidelines , 2019, Annals of Internal Medicine.

[8]  P. Devilee,et al.  Survival after bilateral risk-reducing mastectomy in healthy BRCA1 and BRCA2 mutation carriers , 2019, Breast Cancer Research and Treatment.

[9]  W. Kuhn,et al.  Why the Gold Standard Approach by Mammography Demands Extension by Multiomics? Application of Liquid Biopsy miRNA Profiles to Breast Cancer Disease Management , 2019, International journal of molecular sciences.

[10]  J. Wildberger,et al.  Evaluation of pressure-controlled mammography compression paddles with respect to force-controlled compression paddles in clinical practice , 2019, European Radiology.

[11]  M. Speicher,et al.  Current and future perspectives of liquid biopsies in genomics-driven oncology , 2018, Nature Reviews Genetics.

[12]  N. Karssemeijer,et al.  Reasons for (non)participation in supplemental population-based MRI breast screening for women with extremely dense breasts. , 2018, Clinical radiology.

[13]  M. Ebell,et al.  Cancer screening recommendations: an international comparison of high income countries , 2018, Public Health Reviews.

[14]  K. Kyriacou,et al.  Evaluation of nipple aspirate fluid as a diagnostic tool for early detection of breast cancer , 2018, Clinical Proteomics.

[15]  D. Mislan,et al.  Patient comfort from the technologist perspective: factors to consider in mammographic imaging , 2017, International journal of women's health.

[16]  Karla Kerlikowske,et al.  Women’s experiences and preferences regarding breast imaging after completing breast cancer treatment , 2017, Patient preference and adherence.

[17]  T. Wilt,et al.  Screening for Breast Cancer: U.S. Preventive Services Task Force Recommendation Statement , 2011 .

[18]  J. Lortet-Tieulent,et al.  Breast Cancer Screening for Women at Average Risk: 2015 Guideline Update From the American Cancer Society. , 2015, JAMA.

[19]  Madeleine M A Tilanus-Linthorst,et al.  Influence of tumour stage at breast cancer detection on survival in modern times: population based study in 173 797 patients , 2015, BMJ : British Medical Journal.

[20]  P. V. van Diest,et al.  Repeated Nipple Fluid Aspiration: Compliance and Feasibility Results from a Prospective Multicenter Study , 2015, PloS one.

[21]  Woutjan Branderhorst,et al.  Towards personalized compression in mammography: a comparison study between pressure- and force-standardization. , 2015, European journal of radiology.

[22]  Christoph I. Lee,et al.  Patients’ willingness to participate in a breast cancer biobank at screening mammogram , 2012, Breast Cancer Research and Treatment.

[23]  R. Eeles,et al.  Psychological impact and acceptability of magnetic resonance imaging and X-ray mammography: the MARIBS Study , 2011, British journal of cancer.

[24]  P. V. van Diest,et al.  Successful oxytocin-assisted nipple aspiration in women at increased risk for breast cancer , 2010, Familial Cancer.

[25]  Gerd K Rosenkranz,et al.  A note on the Hodges–Lehmann estimator , 2010, Pharmaceutical statistics.

[26]  E. van der Wall,et al.  Oxytocin: bringing magic into nipple aspiration. , 2007, Annals of oncology : official journal of the European Society for Medical Oncology.

[27]  C. Jacobi,et al.  Risk Estimation for Healthy Women from Breast Cancer Families , 2004, Cancer Epidemiology Biomarkers & Prevention.

[28]  I. Verslegers,et al.  Influence of the radiographer on the pain felt during mammography , 2003, European Radiology.

[29]  S. Steinberg,et al.  Biomarker Assays in Nipple Aspirate Fluid , 2001, The breast journal.

[30]  O. Sartorius.  The biochemistry of breast cyst fluids and duct secretions , 1995, Breast Cancer Research and Treatment.

[31]  P. Philip,et al.  Acetylator status and its relationship to breast cancer and other diseases of the breast. , 1987, European journal of cancer & clinical oncology.

[32]  G. Papanicolaou,et al.  Exfoliative cytology of the human mammary gland and its value in the diagnosis of cancer and other diseases of the breast , 1958 .

[33]  S. Narod,et al.  The relationship between local recurrence and death in early-stage breast cancer , 2015, Breast Cancer Research and Treatment.

[34]  Jeffrey D Blume,et al.  Reasons women at elevated risk of breast cancer refuse breast MR imaging screening: ACRIN 6666. , 2010, Radiology.

[35]  Hilde van der Togt,et al.  Publisher's Note , 2003, J. Netw. Comput. Appl..

[36]  W..  The biochemistry of breast cyst fluids and duct secretions , 2022 .